FEATURED EDITORIAL
Unlike most other drugs, advanced therapies require complex, purpose-built supply chain networks. Making them requires cross-sector collaboration.
- Outsourcing? When Both Sides Of The Table Are Investor-Backed, Everything Changes
- A Biotech Business Model That's Investor-Friendly
- The Supreme Court Rules On Trump Tariffs. Why Shout "Hooray!"?
- Dynamic Flux Analysis Offers Faster Metabolic Modeling Than DOE
- Six Specialized Modalities Testing CDMO Readiness In 2026
- Green Supply Chains Rarely Start With A Pledge; Target Waste Instead
- The Real Reason We Haven't Fully Automated Cell Therapy Yet
GUEST COLUMNISTS
-
Dynamic Flux Analysis Offers Faster Metabolic Modeling Than DOE
By continuously analyzing spent media, researchers can estimate reaction rates at regular time points, providing a granular view of cell metabolism.
-
Green Supply Chains Rarely Start With A Pledge; Target Waste Instead
Effective sustainability strategies in pharma supply chains reduce rework and overage. Three leakage points offer the most practical starting point for rooting out waste.
-
The Real Reason We Haven't Fully Automated Cell Therapy Yet
Manual cell therapy workflows often set the tone for automation. This discussion suggests the approach is flawed and presents automation as a chance to innovate.
-
The Firefighting Era Of Clinical Supply Chain Is Over. Here's What Replaces It
Clinical trial supply chains are evolving: digital twins, on-demand kits, and sustainable logistics replace reactive firefighting with precision, speed, and resilience.
-
The Hidden Engineering Behind Successful Upstream Bioprocessing
In upstream biopharmaceutical production, manufacturing is inseparable from biology, engineering, contamination control, and quality science.
-
A Practical Look At Modern Downstream Processing For Biologics
Part 2 in a series about current bioprocessing practices explores the latest in separation, purification, sterile filtration and aseptic filling.
-
Process Engineering's Key Role In Sterile Injectable Facility Design
Quality requirements for parenteral drugs complicate facility design like few other regulated products. If you're developing injectables, be aware of these key issues.
-
What To Know About — And How To Apply For — FDA's PreCheck Pilot
FDA has now provided specific eligibility and selection criteria for the PreCheck Pilot Program and a timeline for next steps.
PHARMA OUTSOURCING WHITE PAPERS
-
Aggregation In Antibody-Drug Conjugates: Causes And Mitigation
Discover how early intervention in ADC development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.
-
Unlock The Potential Of Pharmacovigilance Outsourcing
Outsourcing pharmacovigilance can reduce overhead, strengthen compliance, and free teams to focus on innovation. Examine what a well-structured global PV model actually looks like in practice.
-
Building Excellence In Pharma Manufacturing Through Rigor
A rigorous, proactive approach is essential for excellence in pharmaceutical manufacturing. Learn how embedding rigor in systems, workflows, and workforce capabilities improves compliance and efficiency.
-
Reducing ADC Timelines With Integrated Development And Manufacturing
ADCs have proven to be highly effective in cancer treatment, but their manufacturing poses challenges. Learn how a CDMO partner can help bring these treatments to patients safely and efficiently.
-
Key Selection Criteria For Cell & Gene Therapy CDMOs
Choosing the right CDMO requires early internal assessment plus strong technical capability, agility, advocacy, clear communication, and long‑term alignment to meet evolving cell and gene therapy needs.
-
A Shift Towards Biofluorescent Particle Counters In Manufacturing
Sterility in injectable drug manufacturing is vital for patient safety and efficiency. Discover how biofluorescent particle counters revolutionize contamination control, regulatory compliance, and operational excellence in modern pharma.
PHARMA OUTSOURCING APP NOTES & CASE STUDIES
- Analytical Method Release And Stability Platform For RNA Drug Substance
- Best Practices For Oncolytic Virus Design, Development, Manufacturing
- Long-Term Container Closure Integrity Testing Of Vial-Stopper-Seal Combinations
- Sterilizing Grade Filter Performance With Biologic Drugs
- Evaluation Of Extractables And Physical Compatibility Of The Mobius® ADC Reactor Single-Use Components For ADC Manufacturing
REPORTING
PRODUCTS & SERVICES
ON-DEMAND WEBINARS
- From Model To Molecule: Combining AI And Experimental Strategies To Transform Drug Development
- Strategies For Robust Process Characterization And Validation To Accelerate Biologics Manufacturing
- Translating Stem Cell Programs To GMP
- Innovating Upstream Manufacturing For The Next Wave Of Gene Therapies
- Where Biologic Stability Programs Fail—and How ICH Q1 Can Help You Get It Right